Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp. reports developments tied to its hormone optimization and healthy aging business, which supports Biote-certified medical providers through training, practice development, operational services and personalized hormone therapy programs. Company updates commonly cover procedure revenue, dietary supplement sales, new provider and clinic growth, commercial team expansion and technology or sales investments aimed at the practitioner network.
Biote news also includes quarterly financial results, outlook commentary, share repurchases, organizational changes and product-supply matters. Its operating updates distinguish procedure-based revenue from Biote-branded dietary supplements and have included disclosures related to Asteria Health, the company’s wholly owned 503B manufacturing subsidiary.
Biote Corp. (NASDAQ: BTMD) announced it will release its fourth quarter and full year financial results on March 28, 2023, after market close. A conference call is scheduled for March 29, 2023, at 8:30 a.m. ET. Biote specializes in preventive health care through personalized hormone therapy and operates in a $7 billion global market for hormone-related aging conditions. Biote trains medical providers to identify and treat these conditions, aiming for enhanced patient outcomes and clinic success.
biote Corp. (NASDAQ: BTMD) has completed its underwritten public offering of 8.5 million shares of Class A common stock at $3.00 per share, including the exercise of underwriters’ option for 1.1 million shares. Notably, Biote is not receiving any proceeds from this offering, which was previously registered with the SEC. The offering is part of a strategic initiative to enhance market presence in the $7 billion hormone optimization market, delivering personalized health care through certified medical providers.
biote Corp. (NASDAQ: BTMD) announced a public offering of 7,391,305 shares of its Class A common stock at $3.00 per share, totaling approximately $22.17 million. The offering, set to close around January 9, 2023, involves selling stockholders, and the company will not receive proceeds from this transaction. Underwriters have a 30-day option to purchase an additional 1,108,695 shares. The registration statement was effective as of January 4, 2023, and the preliminary prospectus is available on the SEC's website.
Biote Corp. (Nasdaq: BTMD) has announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. CEO Terry Weber will present on November 15, 2022, at 12:20 p.m. local time, followed by a Q&A session with CFO Samar Kamdar. A live audio webcast of the presentation will be available here. Biote specializes in personalized hormone therapy, targeting a $7 billion market in preventive healthcare.
Biote (NASDAQ: BTMD) announced strong third-quarter results for 2022, achieving $42 million in revenue, marking an 18% year-over-year increase. Despite a net loss of $(6.3) million and fully diluted GAAP EPS of $(1.74), adjusted EBITDA grew to $12.2 million, a 19% increase compared to the previous year. The company expects to meet the upper end of its guidance for annual revenue at $160-$166 million and adjusted EBITDA at $47-$51 million. The management highlighted ongoing expansion in sales and operations.
biote Corp. (Nasdaq: BTMD) has appointed Debby Morris to its Board of Directors, enhancing its focus on growth within the preventive health care sector. Morris brings over 30 years of financial leadership experience, previously serving as CFO at Apria, Inc., and in various executive roles. CEO Terry Weber emphasized her expertise will strengthen the Board as Biote implements its growth strategies in the $7 billion hormone optimization market. Morris expressed enthusiasm for contributing to Biote’s expansion and success.
biote Corp. (Nasdaq: BTMD) will release its third quarter financial results on November 8, 2022, post-market. A conference call to discuss these results is scheduled for November 9, 2022, at 8:30 a.m. ET. Biote focuses on preventive healthcare through personalized hormone therapies, addressing a $7 billion global market. The company trains medical practitioners to identify and treat symptoms of hormone-related aging conditions, enhancing clinic success.
Biote Corp. (Nasdaq: BTMD) has released an updated Corporate Presentation aimed at investors, available on the company's website. The presentation outlines Biote's growth in the hormone optimization space, emphasizing its franchise-like model that supports practitioners in establishing hormone therapy centers. The company focuses on training these practitioners to identify and treat hormone-related aging conditions. Investors are cautioned that forward-looking statements in the presentation carry risks, including market acceptance and regulatory challenges.
Biote Corp. (Nasdaq: BTMD) has partnered with IMAC Holdings (Nasdaq: BACK) to introduce Biote's hormone optimization services in IMAC's outpatient clinics. This collaboration aims to enhance patient care by integrating innovative treatments for obesity and chronic pain. Training for IMAC professionals on the Biote Method is set to begin in September. Biote specializes in building medical practices focused on hormone optimization, while IMAC provides regenerative rehabilitation for musculoskeletal and neurological conditions.
Biote Corp. has received approval from The Nasdaq Stock Market to relist its common stock and warrants. Trading will resume under the ticker symbols BTMD for common stock and BTMDW for warrants starting on August 29, 2022. CEO Terry Weber expressed gratitude for Nasdaq's support in confirming the company meets the initial listing criteria. Biote operates within the hormone optimization sector, providing practitioners with the necessary tools to establish and run hormone therapy centers.